[2] [2] GALLO R L, GRANSTEIN R D, KANG S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the national rosacea society expert committee［J］. Journal of the American Academy of Dermatology, 2018, 78(1): 148-155.

[3] [3] HUSEIN-ELAHMED H, STEINHOFF M. Laser and light-based therapies in the management of rosacea: an updated systematic review［J］. Lasers in Medical Science, 2021, 36(6): 1151-1160.

[5] [5] LONNE-RAHM S, NORDLIND K, EDSTR?M D W, et al. Laser treatment of rosacea: a pathoetiological study［J］. Archives of Dermatology, 2004, 140(11): 1345-1349.

[6] [6] BAEK J O, HUR H, RYU H R, et al. Treatment of erythematotelangiectatic rosacea with the fractionation of high-fluence, long-pulsed 595 nm pulsed dye laser［J］. Journal of Cosmetic Dermatology, 2017, 16(1): 12-14.

[7] [7] TIERNEY E, HANKE C W. Randomized controlled trial: comparative efficacy for the treatment of facial telangiectasias with 532 nm versus 940 nm diode laser［J］. Lasers in Surgery and Medicine, 2009, 41(8): 555-562.

[8] [8] CARNIOL P J, PRICE J, OLIVE A. Treatment of telangiectasias with the 532 nm and the 532/940 nm diode laser［J］. Facial Plastic Surgery, 2005, 21(2): 117-119.

[9] [9] BERNSTEIN E F, SCHOMACKER K, PARANJAPE A, et al. Pulsed dye laser treatment of rosacea using a novel 15 mm diameter treatment beam［J］. Lasers in Surgery and Medicine, 2018, 50(8): 808-812.

[10] [10] BULBUL B E, AKIN B A. Evaluation of long-term efficacy, safety, and effect on life quality of pulsed dye laser in rosacea patients［J］. Journal of Cosmetic and Laser Therapy, 2019, 21(4): 185-189.

[11] [11] SODHA P, SUGGS A, MUNAVALLI G S, et al. A randomized controlled pilot study: combined 595 nm pulsed dye laser treatment and oxymetazoline hydrochloride topical cream superior to oxymetazoline hydrochloride cream for erythematotelangiectatic rosacea［J］. Lasers in Surgery and Medicine, 2021, 53(10): 1307-1315.

[12] [12] OSMAN M, SHOKEIR H A, HASSAN A M, et al. Pulsed dye laser alone versus its combination with topical ivermectin 1% in treatment of rosacea: a randomized comparative study［J］. The Journal of Dermatological Treatment, 2022, 33(1): 184-190.

[13] [13] AL-NIAIMI F, GLAGOLEVA E, ARAVIISKAIA E. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing［J］. Dermatologic Therepy, 2020, 33(6): e13976.

[17] [17] KIM B Y, MOON H R, RYU H J. Comparative efficacy of short-pulsed intense pulsed light and pulsed dye laser to treat rosacea［J］. Journal of Cosmetic and Laser Therapy, 2019, 21(5): 291-296.

[18] [18] HUSEIN-ELAHMED H, STEINHOFF M. Light-based therapies in the management of rosacea: a systematic review with meta-analysis［J］. International Journal of Dermatology, 2022, 61(2): 216-225.

[19] [19] VISSING A E, DIERICKX C, KARMISHOLT K E, et al. Topical brimonidine reduces IPL-induced erythema without affecting efficacy: a randomized controlled trial in patients with facial telangiectasias［J］. Lasers in Surgery and Medicine, 2018, 50(10): 1002-1009.

[26] [26] TSUNODA K, AKASAKA K, AKASAKA T, et al. Successful treatment of erythematotelangiectatic rosacea with intense pulsed light: report of 13 cases［J］. The Journal of Dermatology, 2018, 45(9): 1113-1116.

[28] [28] HOFMANN M A, LEHMANN P. Physical modalities for the treatment of rosacea［J］. Journal of the German Society of Dermatology, 2016, 14(s6): 38-43.

[29] [29] KWON W J, PARK B W, CHO E B, et al. Comparison of efficacy between long-pulsed Nd:YAG laser and pulsed dye laser to treat rosacea-associated nasal telangiectasia［J］. Journal of Cosmetic and Laser Therapy, 2018, 20(5): 260-264.

[30] [30] ROSE A E, GOLDBERG D J. Successful treatment of facial telangiectasias using a micropulse 1 064 nm neodymium-doped yttrium aluminum garnet laser［J］. Dermatologic Surgery, 2013, 39(7): 1062-1066.

[31] [31] MICALI G, DALL’OGLIO F, VERZì A E, et al. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component［J］. Lasers in Medical Science, 2018, 33(6): 1397-1400.

[32] [32] BARTON J K, FRANGINEAS G, PUMMER H, et al. Cooperative phenomena in two-pulse, two-color laser photocoagulation of cutaneous blood vessels［J］. Photochemistry and Photobiology, 2001, 73(6): 642-650.

[33] [33] RANDEBERG L L, BONESR?NNING J H, DALAKER M, et al. Methemoglobin formation during laser induced photothermolysis of vascular skin lesions ［J］. Lasers in Surgery and Medicine, 2004, 34(5): 414-419.

[36] [36] CAMPOS M A, SOUSA A C, VARELA P, et al. Comparative effectiveness of purpuragenic 595 nm pulsed dye laser versus sequential emission of 595 nm pulsed dye laser and 1 064 nm Nd:YAG laser: a double-blind randomized controlled study［J］. Acta Dermatovenerologica Alpina, Pannonica et Adriatica, 2019, 28(1): 1-5.

[37] [37] MICALI G, GERBER P A, LACARRUBBA F, et al. Improving treatment of erythematotelangiectatic rosacea with laser and/or topical therapy through enhanced discrimination of its clinical features［J］. The Journal of Clinical and Aesthetic Dermatology, 2016, 9(7): 30-39.

[38] [38] UEBELHOER N S, BOGLE M A, STEWART B, et al. A split-face comparison study of pulsed 532 nm KTP laser and 595 nm pulsed dye laser in the treatment of facial telangiectasias and diffuse telangiectatic facial erythema［J］. Dermatologic Surgery, 2007, 33(4): 441-448.

[39] [39] BECHER G L, CAMERON H, MOSELEY H. Treatment of superficial vascular lesions with the KTP 532 nm laser: experience with 647 patients［J］. Lasers in Medical Science, 2014, 29(1): 267-271.

[40] [40] HOFMANN M A, KOKOLAKIS G. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea［J］. Journal of Cosmetic and Laser Therapy, 2017, 19(4): 222-224.

[41] [41] ERTA? R, YAMAN O, AKKU? M R, et al. The rapid effect of pulsed dye laser on demodex density of facial skin［J］. Journal of Cosmetic and Laser Therapy, 2019, 21(3): 123-126.

[42] [42] CLATICI V G, VOICU C, BARINOVA E, et al. Comments on “the decrease of demodex density after Nd:YAG laser application for facial telengiactasias: a case report”［J］. Dermatologc Therepy, 2020, 33(6): e14458.

[43] [43] TEMIZ S A, DURMAZ K, I?IK B, et al. The effect of 577 nm Pro-Yellow laser on demodex density in patients with rosacea［J］. Journal of Cosmetic Dermatology, 2022, 21(1): 242-246.

[44] [44] MOHAMED E M, MOHAMED T K, HASSAN A W. Successful treatment of facial vascular skin diseases with a 577 nm Pro-Yellow laser［J］. Journal of Cosmetic Dermatology, 2019, 18(6): 1675-1679.

[45] [45] KAPICIOGLU Y, SARAC G, CENK H. Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577 nm Pro-Yellow laser: a case series［J］. Lasers in Medical Science, 2019, 34(1): 93-98.

[46] [46] AKSOY S G, ONDER M. Evaluation of the efficacy of Pro-Yellow laser in the management of vascular skin disorders［J］. Journal of Cosmetic Dermatology, 2022, 21(3): 1018-1022.

[47] [47] HAMBLIN M R. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation［J］. AIMS Biophysics, 2017, 4(3): 337-361.

[49] [49] ANDERS J J, LANZAFAME R J, ARANY P R. Low-level light/laser therapy versus photobiomodulation therapy［J］. Photomedicine and Laser Surgery, 2015, 33(4): 183-184.

[50] [50] CATERINA M J, PANG Z. TRP channels in skin biology and pathophysiology［J］. Pharmaceuticals (Basel), 2016, 9(4): 77.

[51] [51] DE MARCHI T, LEAL J E, BORTOLI C, et al. Low-level laser therapy (LLLT) in human progressive-intensity running: effects on exercise performance, skeletal muscle status, and oxidative stress［J］. Lasers in Medical Science, 2012, 27(1): 231-236.

[52] [52] TATMATSU-ROCHA J C, FERRARESI C, HAMBLIN M R, et al. Low-level laser therapy (904 nm) can increase collagen and reduce oxidative and nitrosative stress in diabetic wounded mouse skin［J］. Journal of Photochemistry and Photobiology B: Biology, 2016, 164: 96-102.

[53] [53] YAMAURA M, YAO M, YAROSLAVSKY I, et al. Low level light effects on inflammatory cytokine production by rheumatoid arthritis synoviocytes［J］. Lasers in Surgery and Medicine, 2009, 41(4): 282-290.

[54] [54] HWANG M H, SHIN J H, KIM K S, et al. Low level light therapy modulates inflammatory mediators secreted by human annulus fibrosus cells during intervertebral disc degeneration in vitro［J］. Photochemistry and Photobiology, 2015, 91(2): 403-410.

[55] [55] LIM W, CHOI H, KIM J, et al. Anti-inflammatory effect of 635?nm irradiations on in vitro direct/indirect irradiation model［J］. Journal of Oral Pathology & Medicine, 2015, 44(2): 94-102.

[56] [56] CHEN A C, HUANG Y Y, SHARMA S K, et al. Effects of 810 nm laser on murine bone-marrow-derived dendritic cells［J］. Photomedicine and Laser Surgery, 2011, 29(6): 383-389.

[57] [57] SORBELLINI E, DE PADOVA M P, RINALDI F. Coupled blue and red light-emitting diodes therapy efficacy in patients with rosacea: two case reports［J］. Journal of Medical Case Reports, 2020, 14(1): 22.

[58] [58] GUPTA A, DAI T, HAMBLIN M R. Effect of red and near-infrared wavelengths on low-level laser (light) therapy-induced healing of partial-thickness dermal abrasion in mice［J］. Lasers in Medical Science, 2014, 29(1): 257-265.

[59] [59] NIKOLIS A, BERNSTEIN S, KINNEY B, et al. A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light on facial rejuvenation［J］. Clinical, Cosmetic and Investigational Dermatology, 2016, 9: 115-125.

[61] [61] SANNINO M, LODI G, DETHLEFSEN M W, et al. Fluorescent light energy: treating rosacea subtypes 1, 2, and 3［J］. Clinical Case Reports, 2018, 6(12): 2385-2390.

[62] [62] WADE M, CHAREST V, BALLARDIN B, et al. Biophotonic therapy with fluorescent light energy decreases facial erythema, improves signs and symptoms of rosacea, and increases patient satisfaction: a postmarket study［J］. The Journal of Clinical and Aesthetic Dermatology, 2021, 14(7): 16-21.